International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery
Fu M, Zhao R, Cao Y, Nan Y, Fan L, Liu Z
Gynecological cancers, including ovarian, cervical, and endometrial cancers, remain major contributors to female morbidity and mortality worldwide. Conventional treatments-surgery, chemotherapy, and radiotherapy-have improved outcomes, but advanced or recurrent disease is still associated with poor prognosis…
Read the article →Frontiers in pharmacology2026ReviewNon-viral Gene DeliveryDrug Delivery
Rachamala Hk, Atla S, Angom Rs
Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated…
Read the article →Signal Transduction and Targeted Therapy2021ReviewNon-viral Gene Delivery
Chen L, Hong W, Ren W, Xu T, Qian Z, He Z.
Synthetic nanoparticles face physiological barriers, RES clearance, and unintended biological interactions despite PEGylation and ligand grafting. Biological vectors—cell membranes, extracellular vesicles (EVs), and viruses—offer biocompatibility, biodegradability, immune evasion, and natural targeting. This review…
Read the article →Nature Reviews Materials2021ReviewDrug Delivery
Mandana T. Manzari, Yosi Shamay, Hiroto Kiguchi, Neal Rosen, Maurizio Scaltriti, And Daniel A. Heller
Precision medicine has transformed cancer therapy by enabling molecular profiling and optimised drug design, but clinical translation of many precision therapeutics is hindered by pharmacological limitations, including toxicities and drug resistance. Drug delivery materials can modulate a drug’s pharmacokinetics…
Read the article →APL Bioengineering2021ReviewNon-viral Gene Delivery
Matthew R. Aronson, Scott H. Medina, Michael J. Mitchell
Most clinically approved cancer therapies are potent and toxic small molecules limited by severe off-target toxicities and poor tumour-specific localisation. Liposomal encapsulation reduces toxicity, but reliance on passive targeting via the enhanced permeability and retention (EPR) effect leaves unresolved issues…
Read the article →Human Gene Therapy* (as indicated by article context and references)2018ReviewNon-viral Gene Delivery
Yao Xiao, Kun Shi, Ying Qu, Bingyang Chu, Zhiyong Qian
In the past 10 years, many clinical nano-gene therapy trials have been discontinued due to poor efficacy and serious side effects. There is a critical need to design suitable gene delivery systems that can protect nucleic acids, enhance transfection efficiency, penetrate deep into tumours, and remain stable and safe…
Read the article →2017ReviewDrug Delivery
Liposomes are the first nano drug delivery systems successfully translated into clinical use, but many formulations still face limitations in biodistribution, toxicity, stability, and target selectivity. An updated review was needed to summarise liposome technologies, marketed clinical products, formulation aspects…
Read the article →Journal of Drug Targeting (J Drug Target)2013ReviewNon-viral Gene Delivery
Jing Yao, Ying Fan, Yuanke Li, And Leaf Huang
Non-viral gene delivery systems are safer than viral vectors but are highly inefficient at nuclear delivery. Only ~10–20% of applied plasmid DNA enters targeted cells, and only ~1–5% of the applied dose reaches the nucleus. The nuclear envelope is a major barrier to transgene delivery, and there is a need for “smart”…
Read the article →Journal of drug targeting2008ReviewDrug Delivery
Parveen, S.; Sahoo, S. K
Conventional cancer chemotherapy suffers from poor tumour selectivity, high required doses, systemic toxicity, rapid drug elimination, and multidrug resistance. Polymeric nanoparticles (NPs) are reviewed as a strategy to improve targeted delivery, controlled release, and therapeutic efficacy while reducing adverse…
Read the article →